BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.

In a pilot study to reduce the duration of treatment and potential long-term toxicities, 39 patients with acute promyelocytic leukemia in remission received a single cycle of intensive consolidation therapy, followed by intermittent ATRA maintenance.

Seven patients have relapsed; all other patients are in molecular remission (median follow-up, 2.75 years).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow / metabolism. Humans. Incidence. Infection / chemically induced. Infection / epidemiology. Middle Aged. Myelodysplastic Syndromes / chemically induced. Neoplasm Recurrence, Local / epidemiology. Pilot Projects. Receptors, Retinoic Acid / metabolism. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Stomatitis / chemically induced. Stomatitis / epidemiology. Survival Analysis. Treatment Outcome. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15929100.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia: from highly fatal to highly curable.

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia.

Morphologically, it is identified as the M3 subtype of acute myeloid leukemia by the French-American-British classification and cytogenetically is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion between promyelocytic leukemia (PML) gene and retinoic acid receptor alpha (RARalpha).

It seems that the disease is the most malignant form of acute leukemia with a severe bleeding tendency and a fatal course of only weeks.

Chemotherapy (CT; daunorubicin, idarubicin and cytosine arabinoside) was the front-line treatment of APL with a complete remission (CR) rate of 75% to 80% in newly diagnosed patients.

Despite all these progresses, the median duration of remission ranged from 11 to 25 months and only 35% to 45% of the patients could be cured by CT.

[MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18299451.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 111

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m (2)) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

[MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Dose-Response Relationship, Drug. Humans. Male. Remission Induction

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17768126.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] Italy

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.

BACKGROUND: Acute myeloid leukemia (AML) carries a dismal prognosis in older patients.

Of 64 patients who had pathologically confirmed AML, excluding patients with acute promyelocytic leukemia and using World Health Organization criteria, the median age was 71 years, 10 patients (16%) had treatment-related AML, 40 patients (63%) had an antecedent myelodysplastic syndrome or myeloproliferative disorder, and 35 patients (55%) had unfavorable cytogenetics.

RESULTS: Complete remission was achieved in 21 of 61 patients (34%), including 15 of 50 patients (30%) who had secondary or treatment-related AML, 10 of 33 patients (30%) who had unfavorable cytogenetics, and 6 of 34 patients (18%) who had a poor baseline performance status.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Aged. Aged, 80 and over. Arsenicals / administration & dosage. Cytarabine / administration & dosage. Female. Humans. Leukemia, Promyelocytic, Acute. Male. Middle Aged. Oxides / administration & dosage. Prognosis. Remission Induction. Survival Rate

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18825661.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 04079A1RDZ / Cytarabine; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] First reported case of aplastic anemia occurring in a patient after acute promyelocytic leukemia in remission.

[MeSH-major] Anemia, Aplastic / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Humans. Idarubicin / adverse effects. Male. Remission Induction. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Anemia.

Genetic Alliance. consumer health - Aplastic Anemia.

MedlinePlus Health Information. consumer health - Aplastic Anemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20040907.001).

[ISSN] 1543-0790

[Journal-full-title] Clinical advances in hematology & oncology : H&O

[ISO-abbreviation] Clin Adv Hematol Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of international collaboration on the prognosis of childhood acute promyelocytic leukemia in Iraq.

As a consequence of a collaborative project between the Al Mansour Hospital for Pediatrics in Baghdad and the Pediatric Unit of Hematology of "La Sapienza" University, in Rome, in October 2003 a specific all-trans-retinoic acid-based protocol was designed in order to offer a modern therapeutic program for the management of Iraqi children with acute promyelocytic leukemia, adapted to the severe local difficulties.

The preliminary encouraging results represent a substantial improvement over the earlier experience in childhood acute promyelocytic leukemia in Iraq.

[MeSH-major] Leukemia, Promyelocytic, Acute / therapy. Tretinoin / administration & dosage

[MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Cooperative Behavior. Developing Countries. Humans. Infant. International Cooperation. Iraq. Italy. Prognosis. Remission Induction. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16533724.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] Italy

[Chemical-registry-number] 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia.

In addition to choosing a state-of-the-art regimen including all-transretinoic and anthracycline chemotherapy, modern management of acute promyelocytic leukemia (APL) implies the adoption of appropriate supportive measures, rapid establishment of an accurate genetic diagnosis, correct assessment of response to therapy and evaluation of the risk of disease recurrence by molecular monitoring.

[MeSH-major] Hematology / methods. Leukemia, Promyelocytic, Acute / therapy

[MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Male. Middle Aged. Pregnancy. Recurrence. Remission Induction. Risk

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15951298.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Italy

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 38

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

An understanding of the prognostic factors associated with the various forms of induction mortality in patients with acute promyelocytic leukemia (APL) has remained remarkably limited.

Complete remission was attained in 666 patients (91%).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hemorrhage / mortality. Infection / mortality. Leukemia, Promyelocytic, Acute / mortality

[MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Blast Crisis / blood. Blast Crisis / drug therapy. Blast Crisis / mortality. Child. Child, Preschool. Creatinine / blood. Disease-Free Survival. Female. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Male. Middle Aged. Remission Induction. Risk Factors. Sex Factors. Survival Rate. Syndrome. Treatment Failure. Tretinoin / administration & dosage. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Bleeding.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18195095.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 5688UTC01R / Tretinoin; AYI8EX34EU / Creatinine; ZRP63D75JW / Idarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Hematopoietic stem cell transplantation in the second or later complete remission in acute promyelocytic leukemia initially treated with all-trans retinoic acid].

Despite the use of all-trans retinoic acid (ATRA) as the first-line treatment for acute promyelocytic leukemia (APL), relapse occurs in about 20% of cases.

Most relapsing APL patients can achieve second remission (CR2) following ATRA combined with chemotherapy or arsenic trioxide.

Complete molecular remission has been maintained in the remaining 2 patients.

Complete molecular remission has been maintained in all 4 patients (mean follow-up, 3 years 9 months).

[MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Promyelocytic, Acute / therapy. Tretinoin / therapeutic use

[MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Retrospective Studies. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16440769.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Adams-Stokes attack due to complete atrioventricular block in a patient with acute promyelocytic leukemia during remission induction therapy using all-trans retinoic acid].

Remission induction therapy was performed for a 46-year-old Japanese man with acute promyelocytic leukemia using ATRA (45 mg/m2), enocitabine (170 mg/m2, 5 days), and mitoxantrone (4 mg/m2, 3 days).

The normal sinus rhythm was restored 15 days thereafter, and the patient eventually reached remission.

[MeSH-major] Heart Block / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects

[MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Cytarabine / analogs & derivatives. Drug Administration Schedule. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Pacemaker, Artificial. Remission Induction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16447716.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; 9YVR68W306 / enocitabine; BZ114NVM5P / Mitoxantrone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.

All-trans retinoic acid (ATRA) can induce complete remission in acute promyelocytic leukemia (APL), but resistance to this treatment develops rapidly partly due to increased ATRA metabolism.

Among the cytochrome P450s (CYPs) involved in ATRA metabolism, the ATRA-inducible cytochrome P450 26A1 (CYP26A1) is particularly active although the molecular mechanisms involved in its regulation are not well defined in the target leukemia cells.

To study CYP26A1 expression and regulation in APL cells, we used the NB4 promyelocytic leukemia cell line.

To further define CYP26A1 induction mechanisms in the NB4 leukemia cells, we used RARs and RXR selective agonists.

In conclusion, we have shown that CYP26A1 induction is not essential for the granulocytic maturation of NB4 leukemia cells, and that CYP26A1 induction requires the activation of both RARalpha and RXR in these cells.

[MeSH-major] Cytochrome P-450 Enzyme System / biosynthesis. Leukemia, Promyelocytic, Acute / enzymology. Receptors, Retinoic Acid / agonists. Retinoid X Receptors / agonists

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15896339.001).

[ISSN] 0006-2952

[Journal-full-title] Biochemical pharmacology

[ISO-abbreviation] Biochem. Pharmacol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia].

A 37-year-old woman was diagnosed with therapy-related acute promyelocytic leukemia (t-APL) in May 2006 after chemotherapy that included etoposide for ovarian cancer in November 2003.

After treatment with all-trans retinoic acid in combination with chemotherapy, complete remission was attained.

Molecular remission was attained without serious complication.

GO is considered a promising agent to achieve molecular remission in patients with relapsed t-APL.

[MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / adverse effects. Etoposide / adverse effects. Leukemia, Promyelocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Female. Humans. Remission Induction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18516871.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / gemtuzumab; 6PLQ3CP4P3 / Etoposide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rational targeting in acute promyelocytic leukemia.

Acute promyelocytic leukemia (ARL) is characterized by the nearly homogeneous expression of the fusion oncogenic protein PML-RARalpha and the testis-specific cyclin A1 protein, which are implicated in its pathogenesis.

PML-RARalpha binds all-trans retinoic acid with high affinity inducing granulocytic differentiation and remission.

[MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20133971.001).

[ISSN] 0258-851X

[Journal-full-title] In vivo (Athens, Greece)

[ISO-abbreviation] In Vivo

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 5688UTC01R / Tretinoin; EC 2.7.11.22 / Cyclin-Dependent Kinases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Acute promyelocytic leukemia associated with hemophagocytic syndrome].

The diagnosis of acute promyelocytic leukemia (APL) associated with hemophagocytic syndrome (HPS) was made.

After administration of dexamethasone and etoposide, DIC and HPS improved, and complete remission of APL was obtained.

[MeSH-major] Leukemia, Promyelocytic, Acute / complications. Lymphohistiocytosis, Hemophagocytic / etiology

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. ETOPOSIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17515122.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] Japan

[Chemical-registry-number] 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; ZRP63D75JW / Idarubicin

[Number-of-references] 14

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].

I report on a 21-year-old man with acute promyelocytic leukemia (APL) which relapsed after a therapeutic regimen consisting of tretinoin, daunorubicin, enocitabine, mitoxantrone, and cytarabine.

The patient achieved molecular remission 103 days after the start of oral As2O3, and remains in remission after an additional 2 courses of oral As2O3 as consolidation chemotherapy.

[MeSH-major] Antineoplastic Agents / administration & dosage. Arsenicals / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / administration & dosage

[MeSH-minor] Administration, Oral. Adult. Humans. Male. Neoplasm Recurrence, Local. Remission Induction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16440808.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [The effects of different post-remission treatment on long-term survival of acute promyelocytic leukemia].

OBJECTIVE: To Summarize and compare the effects of the different post-remission treatment on long-term survival in acute promyelocytic leukemia (APL) patients.

METHODS: The long-term survival and relapse of 111 APL patients with different post-remission treatment were retrospectively analyzed.

CONCLUSION: The APL patients receiving combined post-remission therapy had better OS and RFS those receiving chemotherapy alone.

Sequential therapy combining ATRA, As(2)O(3) and chemotherapy is the best post-remission therapy for long-term survival of APL patients.

[MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / mortality. Remission Induction

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17166449.001).

[ISSN] 0578-1426

[Journal-full-title] Zhonghua nei ke za zhi

[ISO-abbreviation] Zhonghua Nei Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience.

This cohort included 27 (17%) pts with Core Binding Factor (CBF)-AML [inv(16), t(8:21)] and 19 pts (12%) with acute promyelocytic leukemia (APL).

Complete remission (CR) rates were 89% for CBF AML, 79% for APL, and 75% for all other pts.

Outcome is better for pts with CBF leukemia (3 yr survival 56%, sustained CR 49%) and APL (3 yr survival 51%, sustained CR 36%) compared to other AML (3 yr survival 28%, sustained CR 24%).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961415.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML).

We present the results of the first-in-human phase I trial of this agent in patients with AML in complete remission (CR).

METHODS: Patients aged 60-80 years with non promyelocytic AML in first CR following induction and 1-6 cycles of consolidation chemotherapy, normal renal, and hepatic functions, KIR-expression on patient NK-cells and who signed informed consent were eligible.Dose escalation (0.0003, 0.003, 0.015, 0.075, 0.3, 1, 3 mg/kg) was studied using a 3+3 scheme.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962059.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Open issues on bleeding and thrombosis in acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a specific genetic alteration, affecting the retinoic acid receptor-alpha (RAR-alpha), and leading to the accumulation of the promyelocytic blasts in the bone marrow and blood which is frequently associated with a life-threatening consumptive coagulopathy.

The body of biological information on APL establishes this leukemia as a unique entity that has to be promptly recognized to counteract the coagulopathy, especially in light of its striking response to treatment with all-trans retinoic acid.

In fact, the current standard for induction therapy results in extremely high antileukemic efficacy, achieving 90 to 95% complete remission rate.

However, while primary leukemia resistance has virtually disappeared as a cause of remission induction failure, death due to hemorrhage remains the major problem during the early treatment phase.

[MeSH-major] Hemorrhage / diagnosis. Hemorrhage / etiology. Leukemia, Promyelocytic, Acute / complications. Thrombosis / diagnosis. Thrombosis / etiology

[MeSH-minor] Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / epidemiology. Disseminated Intravascular Coagulation / etiology. Disseminated Intravascular Coagulation / therapy. Humans

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Thrombosis.

Genetics Home Reference. consumer health - acute promyelocytic leukemia.

MedlinePlus Health Information. consumer health - Bleeding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20434005.001).

[ISSN] 1879-2472

[Journal-full-title] Thrombosis research

[ISO-abbreviation] Thromb. Res.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 19

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [All-trans retinoic acid-induced erythema nodosum in acute promyelocytic leukemia].

A 24-year-old woman with acute promyelocytic leukemia was treated with all-trans retinoic acid (ATRA) as a remission induction therapy.

Although the administration of ATRA was continued until complete remission of the leukemia, the erythema nodosum rapidly disappeared following short-term steroid therapy and no recurrence was observed.

[MeSH-major] Antineoplastic Agents / adverse effects. Erythema Nodosum / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects

[MeSH-minor] Adult. Female. Fever / chemically induced. Humans. Prednisolone / administration & dosage. Recurrence. Remission Induction. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16447715.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin; 9PHQ9Y1OLM / Prednisolone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Late relapses in acute promyelocytic leukaemia.

From January 1988 to December 1997, among 53 acute promyelocytic leukaemia patients in 1st complete remission (CR) after 5 years from diagnosis, we observed 5 late relapses (9.4%) after 60, 61, 71, 101 and 155 months from diagnosis; 3 of those late relapses (7.7%) occurred among 39 patients previously treated with all-trans-retinoic acid.

In conclusion, a late relapse occurred in a sizeable fraction of acute promyelocytic leukaemia patients: the high rate of ear involvement might be explained considering the ear as a 'disease sanctuary'.

[MeSH-major] Leukemia, Promyelocytic, Acute / pathology

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2007 S. Karger AG, Basel

(PMID = 17135723.001).

[ISSN] 1421-9662

[Journal-full-title] Acta haematologica

[ISO-abbreviation] Acta Haematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Switzerland

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin; AIDA protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Presentation of acute promyelocytic leukemia as granulocytic sarcoma.

This extramedullary tumor can present before, concurrent with or after the diagnosis of acute myeloid leukemia.

GS is extremely uncommon in acute promyelocytic leukemia (APL).

As a proportion of patients never develop systemic disease, correct and timely diagnosis may be rather difficult, but is a prerequisite for optimal outcome.

GS should be considered in the differential diagnosis of children with unusual bone lesions.

[MeSH-major] Diagnostic Errors. Leukemia, Promyelocytic, Acute / complications. Sarcoma, Myeloid / etiology

[MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arthritis, Psoriatic / diagnosis. Biomarkers, Tumor / analysis. Female. Humans. Oncogene Proteins, Fusion / analysis. Osteolysis / etiology. Osteomyelitis / diagnosis. Remission Induction. Shoulder Pain / etiology. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17437290.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia].

A 79-year-old female with acute promyelocytic leukemia (APL) presented with second hematological relapse.

She had been treated previously with modified AIDA protocol as the front-line therapy and had achieved complete remission.

During ATRA maintenance therapy, the first hematological relapse occurred and she was treated with arsenic trioxide (ATO), achieving the second complete remission.

The patient was then treated with two courses of gemtuzumab ozogamicin (GO) and achieved the third complete remission.

At present, she is maintaining molecular remission more than one year after GO treatment.

GO is considered to be a promising agent for elderly patients with relapsed acute promyelocytic leukemia resistant to arsenic trioxide.

[MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Drug Administration Schedule. Female. Humans. Recurrence. Remission Induction. Time Factors. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20467227.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sustained remission achieved with ATRA and chemotherapy in second relapse of acute promyelocytic leukemia in Down syndrome.

Children with Down syndrome (DS) are at an increased risk of developing acute leukemia.

Acute myeloid leukemia predominates among DS children below 4 years of age but acute promyelocytic leukemia (APL) has rarely been reported in DS.

Acute myeloid leukemia in DS is extremely sensitive to treatment but the optimum treatment of de novo or relapsed APL in DS is not known.

We describe a child with DS and APL, who despite having a multiply relapsing course, achieved a third remission with ATRA and chemotherapy, which is sustained with maintenance therapy.

[MeSH-major] Antineoplastic Agents / administration & dosage. Down Syndrome / complications. Leukemia, Promyelocytic, Acute / prevention & control. Tretinoin / administration & dosage

[MeSH-minor] Child, Preschool. Humans. Recurrence. Remission Induction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Down Syndrome.

MedlinePlus Health Information. consumer health - Down Syndrome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19636277.001).

[ISSN] 1536-3678

[Journal-full-title] Journal of pediatric hematology/oncology

[ISO-abbreviation] J. Pediatr. Hematol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

[Number-of-references] 13

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).

Patients with acute promyelocytic leukemia (APML) with the t(11;17) translocation usually respond poorly to all-trans retinoic acid (ATRA) and chemotherapy.

We describe a patient with promyelocytic leukemia zinc finger/retinoic acid receptor alpha (PLZF/RARalpha) APML who was treated with combination chemotherapy after poor response to arsenic trioxide.

He achieved hematological remission in 4 weeks followed by achievement of molecular remission in 8 weeks.

At a follow-up of 32 months after achieving hematological remission, he continues to remain in hematological and molecular remission with normal blood parameters and negative reverse transcriptase polymerase chain reaction (RT-PCR) results.

Combination chemotherapy can achieve sustained remission in patients with PLZF/RARalpha APML.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Proteins / blood. Oncogene Proteins, Fusion / blood

[MeSH-minor] Adult. Arsenicals / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Drug Resistance, Neoplasm. Follow-Up Studies. Humans. Male. Oxides / therapeutic use. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15592671.001).

[ISSN] 0939-5555

[Journal-full-title] Annals of hematology

[ISO-abbreviation] Ann. Hematol.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] Germany

[Chemical-registry-number] 0 / Arsenicals; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / PLZF-RARalpha fusion protein, human; 04079A1RDZ / Cytarabine; S7V92P67HO / arsenic trioxide; ZS7284E0ZP / Daunorubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Acute promyelocytic leukemia with CD59 deficiency].

The study was aimed to investigate whether CD59 is deficient in acute promyelocytic leukemia (APL) blast cells.

The results showed that the deficiency of CD59 expression in 12 out of 19 APL samples was found, its incidence was significantly higher than that in other acute myeloid leukemia (AML) samples (deficiency of CD59 expression in 14 of 40 non-APL AML samples, p=0.042).

The expression of CD59 became normal after the patients achieved complete remission (CR), which indicated that the deficient of CD59 expression was only found in APL blast cells, but also found in APL cell line NB4 cells.

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Cd59 deficiency.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21129240.001).

[ISSN] 1009-2137

[Journal-full-title] Zhongguo shi yan xue ye xue za zhi

[ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi

[Language] CHI

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Antigens, CD59; 0 / Membrane Proteins; 0 / phosphatidylinositol glycan-class A protein; 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) is characterized by generation of the PML-RARalpha fusion gene.

More than 90% of patients with APL achieve a complete remission (CR) with differentiation therapy consisting of ATRA combined with chemotherapy.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Benzoates / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oncogene Proteins, Fusion / antagonists & inhibitors. Oxides / therapeutic use. Tetrahydronaphthalenes / therapeutic use. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71 [11587370.001]

[Cites] Nat Rev Cancer. 2002 Sep;2(9):705-13 [12209159.001]

[Cites] Cell. 1997 May 2;89(3):373-80 [9150137.001]

[Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]

[Cites] Int J Hematol. 2005 Oct;82(3):224-9 [16207595.001]

[Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]

[Cites] Ann Intern Med. 2000 Dec 5;133(11):881-5 [11103058.001]

[Cites] Leukemia. 2003 Aug;17(8):1454-63 [12886231.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2006;:156-61, 514 [17124055.001]

[Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]

[Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]

[Cites] J Biol Chem. 1992 Oct 25;267(30):21486-91 [1328234.001]

[Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]

[Cites] Blood. 2007 Jul 1;110(1):59-66 [17374742.001]

[Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]

[Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]

[Cites] J Med Chem. 1988 Nov;31(11):2182-92 [3184125.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]

[Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]

[Cites] J Cancer Res Clin Oncol. 1995;121(11):696-8 [7593136.001]

[Cites] Leukemia. 2002 Apr;16(4):617-22 [11960341.001]

[Cites] Nature. 1995 Oct 5;377(6548):454-7 [7566127.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]

[Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]

[Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]

[Cites] Nature. 1989 Jun 29;339(6227):714-7 [2544807.001]

[Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]

[Cites] Blood. 1993 Sep 1;82(5):1573-7 [8395911.001]

[Cites] Science. 2002 Feb 8;295(5557):1079-82 [11834837.001]

[Cites] Blood. 1999 Jun 15;93(12):4131-43 [10361110.001]

[Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):485-93 [16937107.001]

[Cites] Int J Hematol. 2000 Dec;72(4):470-3 [11197214.001]

[Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]

[Cites] Arch Biochem Biophys. 1980 Feb;199(2):374-83 [7362233.001]

[Cites] Ann Intern Med. 1996 May 15;124(10):893-6 [8610919.001]

[Cites] Blood. 1996 Jan 15;87(2):725-33 [8555497.001]

[Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2006;:147-55 [17124054.001]

[Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]

(PMID = 17929112.001).

[ISSN] 1341-9625

[Journal-full-title] International journal of clinical oncology

[ISO-abbreviation] Int. J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Benzoates; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Tetrahydronaphthalenes; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 08V52GZ3H9 / tamibarotene; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 46

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission.

Relapse still occurs in approximately 20-30% of patients with acute promyelocytic leukemia (APL) and, after achievement of second complete remission (CR), the optimal strategy is still controversial.

We describe therapeutic results from a series of 13 patients autografted in second molecular remission (MR) by a molecular negative apheresis product.

In all patients, the disease was confirmed at the molecular level and all had received the GIMEMA/AIDA protocol, achieving molecular remission at the end of consolidation.

In all cases, molecular evaluation of the apheresis product was negative for the promyelocytic leukemia/retinoic acid receptor alpha gene.

[MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Promyelocytic, Acute / therapy. Neoplasm Recurrence, Local / therapy. Salvage Therapy / methods

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20944181.001).

[ISSN] 1791-7530

[Journal-full-title] Anticancer research

[ISO-abbreviation] Anticancer Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia during pregnancy.

OBJECTIVE: To report our experience about a woman with acute promyelocytic leukemia (APL) during pregnancy.

PATIENT(S): A 32-year-old-woman, gravida 2, para 1, at the 25th week of pregnancy with a diagnosis of APL.

The mother is now undergoing the third and last consolidation step with good results, and APL is in remission.

[MeSH-major] Leukemia, Promyelocytic, Acute / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Pregnancy.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

(PMID = 20447623.001).

[ISSN] 1556-5653

[Journal-full-title] Fertility and sterility

[ISO-abbreviation] Fertil. Steril.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; ZRP63D75JW / Idarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Effect of post-remission therapy mainly with compound huangdai tablet on long-term survival of patients with acute promyelocytic leukemia].

OBJECTIVE: To investigate the effect of post-remission therapy mainly with Compound Huangdai Tablet (CHDT) on long-term survival of patients with acute promyelocytic leukemia (APL).

METHODS: One hundred and twelve APL patients were treated after remission mainly with CHDT administered alternately with chemotherapeutic projects such as HACP, HAOP, HAEP and HAMP.

CONCLUSION: The post-remission therapy mainly with CHDT is an effective and feasible program for the treatment of APL.

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21302484.001).

[ISSN] 1003-5370

[Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi

[Language] CHI

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Arsenicals; 0 / Drugs, Chinese Herbal

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.

BACKGROUND: Even after the introduction of all-trans retinoic acid (ATRA), early hemorrhagic death remains a major cause of remission induction failure for acute promyelocytic leukemia (APL).

METHODS: To investigate severe hemorrhagic complications during remission induction therapy with respect to incidence, risk factors, and influence on outcome.

Results were analyzed for 279 patients enrolled in the APL97 study conducted by the Japan Adult Leukemia Study Group (JALSG).

Nine of them succumbed to an early death, while the remaining nine patients eventually achieved complete remission (CR).

[MeSH-major] Hemorrhage / etiology. Hemorrhage / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology

[MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17241371.001).

[ISSN] 0902-4441

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] Denmark

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is cytarabine required in the treatment of acute promyelocytic leukemia?

Until the late 1980s, chemotherapy with anthracyclines and cytarabine (AraC) was the only treatment approach for acute promyelocytic leukemia (APL), as for other types of acute myeloid leukemia.

Several groups have reported high rates of complete remission and low rates of relapse with ATRA and chemotherapy using anthracyclines alone, suggesting that AraC could be avoided in the chemotherapy of APL, reducing toxicity.

[MeSH-major] Cytarabine / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Middle Aged. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]

[Cites] Leukemia. 1992;6 Suppl 1:64-6 [1548938.001]

[Cites] Cancer. 1997 Dec 1;80(11 Suppl):2181-5 [9395031.001]

[Cites] Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7 [8916311.001]

[Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]

[Cites] Blood. 1992 Feb 1;79(3):543-53 [1732003.001]

[Cites] Leuk Lymphoma. 1991;4(4):239-48 [27463043.001]

[Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]

[Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]

[Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]

[Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]

[Cites] Blood. 1998 Oct 15;92(8):2712-8 [9763554.001]

[Cites] Blood. 1989 Apr;73(5):1116-22 [2930837.001]

[Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Leukemia. 1994;8 Suppl 2:S38-41 [7815835.001]

[Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]

[Cites] Am J Med. 1984 May;76(5):827-41 [6586073.001]

[Cites] Leukemia. 2005 Feb;19(2):230-3 [15565164.001]

[Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]

[Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]

[Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]

[Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]

[Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]

[Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]

(PMID = 20425342.001).

[ISSN] 1558-822X

[Journal-full-title] Current hematologic malignancy reports

[ISO-abbreviation] Curr Hematol Malig Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin

[Number-of-references] 26

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia treated with idarubicin complicated by focal segmental glomerulosclerosis.

The authors report a 9-year-old boy presenting with a left cerebral ischemic infarction as the first manifestation of acute promyelocytic leukemia.

Remission in bone marrow was achieved with chemotherapy, however, new intracranial ischemic areas developed on follow-up.

Acute promyelocytic leukemia complicated by FSGS has not been previously reported in children.

Thrombosis could be related with both leukemia and nephrotic syndrome, here thrombosis was the initial symptom, before FSGS was diagnosed.

[MeSH-major] Antibiotics, Antineoplastic / adverse effects. Glomerulosclerosis, Focal Segmental / etiology. Idarubicin / adverse effects. Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20048687.001).

[ISSN] 1536-3678

[Journal-full-title] Journal of pediatric hematology/oncology

[ISO-abbreviation] J. Pediatr. Hematol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZRP63D75JW / Idarubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Isolated central nervous system relapse during cytologic and molecular hematologic remission in two patients with acute promyelocytic leukemia.

Extramedullary involvement in the absence of bone marrow disease is rare in patients with acute promyelocytic leukemia (APL).

[MeSH-major] Central Nervous System Neoplasms / etiology. Leukemia, Promyelocytic, Acute / pathology. Tretinoin / adverse effects

[MeSH-minor] Adult. Humans. Male. Recurrence. Remission Induction. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17852441.001).

[ISSN] 1607-8454

[Journal-full-title] Hematology (Amsterdam, Netherlands)

[ISO-abbreviation] Hematology

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

[Chemical-registry-number] 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors].

We have retrospectively evaluated a cohort of 144 patients (including 17 pediatric ones) with de novo acute promyelocytic leukemia registered in databases of institutions cooperating within the CELL group (The Czech Leukemia Study Group for Life).

Of 140 evaluable patients, 97 (69.3%) attained complete remission (CR).

The projected overall survival (OS) 4 years after diagnosis was 58.9%, and 55.3% at 6 years.

Another parameter with a significant impact on attaining CR was the leukocyte (WBC) count at diagnosis: its median values in patients achieving and not achieving CR were 2.1 and 24.0 x 10(9)/l, respectively (P < 0.0001).

The platelet counts at diagnosis had no impact on entering CR.

[MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Survival Rate

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18780575.001).

[ISSN] 0042-773X

[Journal-full-title] Vnitr̆ní lékar̆ství

[ISO-abbreviation] Vnitr Lek

[Language] cze

[Publication-type] English Abstract; Journal Article

[Publication-country] Czech Republic

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Molecular responses in acute promyelocytic leukemia patients monitored by real-time quantitative RT-PCR].

BACKGROUND & OBJECTIVE: Previous clinical and experimental results have indicated a close relationship between residual leukemia cell clones and clinical outcome in acute promyelocytic leukemia (APL) patients.

Real-time fluorescent quantitative reverse transcription-polymerase chain reaction (RQ-RT-PCR) is a sensitive and accurate method in detecting leukemia cell clones and monitoring minimal residual disease (MRD).

METHODS: All-trans retinoic acid (ATRA) and compound Huangdai tablets were used for remission induction in 100 newly diagnosed APL patients.

The NQ of fusion gene transcripts in 33 patients during follow-up decreased from 0.62 at diagnosis to 0.25 at clinical and hematologic remission (CHR) after induction, to 0.000 3 after consolidation chemotherapy and to 0 during maintenance.

[MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18279625.001).

[Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer

[ISO-abbreviation] Ai Zheng

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia.

Serious bleeding and thrombotic complications are frequent in acute promyelocytic leukemia (APL) and are major causes of morbidity and mortality.

Comparison of the various populations of MP was made between samples collected at the time of diagnosis with those collected at molecular remission.

[MeSH-major] Cell-Derived Microparticles / physiology. Hemostasis. Leukemia, Promyelocytic, Acute / blood

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] © Thieme Medical Publishers.

(PMID = 21049391.001).

[ISSN] 1098-9064

[Journal-full-title] Seminars in thrombosis and hemostasis

[ISO-abbreviation] Semin. Thromb. Hemost.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia: what are the treatment options?

IMPORTANCE OF THE FIELD: Acute promyelocytic leukemia (APL) represents a paradigm of therapeutic success in clinical hematology.

Since the introduction of all-trans-retinoic-acid in the early 1980s, complete remission rates exceed 90% and the cure rate is > 70%.

AREAS COVERED IN THIS REVIEW: The aim of this article is to focus on still controversial issues in the management of APL, such as the role of arsenic trioxide as front-line therapy, the management of older unfit patients, the potential utility of gemtuzumab-ozogamycin and the effectiveness (if any) of maintenance therapy for patients in molecular remission.

In addition, the possibility of reducing the intensity of post-remission therapy, which is associated with substantial morbidity in potentially cured patients, is discussed.

[MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

[MeSH-minor] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Hematopoietic Stem Cell Transplantation. Humans. Remission Induction. Secondary Prevention. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20163270.001).

[ISSN] 1744-7666

[Journal-full-title] Expert opinion on pharmacotherapy

[ISO-abbreviation] Expert Opin Pharmacother

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 75

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Monitoring of minimal residual disease in patients with acute promyelocytic leukemia].

AIM: To study efficacy of different programs of maintenance therapy, to create the program of differential therapy of minimal residual disease (MRD) and molecular recurrences at all stages of acute promyelocytic leukemia (APL) basing on the results of monitoring.

Therapeutic policy is determined after diagnosis of molecular recurrence.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Leukemia, Promyelocytic, Acute / blood. Neoplasm Proteins / blood. Oncogene Proteins, Fusion / blood

[MeSH-minor] Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Neoplasm, Residual. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16944747.001).

[ISSN] 0040-3660

[Journal-full-title] Terapevticheskiĭ arkhiv

[ISO-abbreviation] Ter. Arkh.

[Language] rus

[Publication-type] English Abstract; Journal Article

[Publication-country] Russia (Federation)

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia.

We describe a patient with acute promyelocytic leukemia (APL) and the karyotype 46,XX,i(17)(q10) with PML-RARA fusion gene detected by fluorescence in situ hybridization (FISH) and nested reverse transcriptase-polymerase chain reaction (RT-PCR).

FISH using dual-color translocation probes for PML (promyelocytic leukemia) and RARA (retinoic acid receptor-alpha) showed fusion signal for PML-RARA on both arms of i(17q).

The patient attained complete remission (CR) with all-trans retinoic acid treatment and became PML-RARA negative.

Bone marrow examination suggested an acute monoblastic leukemia (AML-M5a) including the karyotype 46,XX,t(8;16) (p11.2;p13.3),inv(11)(p15q22 approximately q23)[11]/47,idem,+i(8)(q10)[9].

The occurrence of therapy related acute leukemia after successful therapy for APL is an emerging problem.

[MeSH-major] Antineoplastic Agents / adverse effects. Chromosomes, Human, Pair 17. Isochromosomes. Leukemia, Monocytic, Acute / chemically induced. Leukemia, Promyelocytic, Acute / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Receptors, Retinoic Acid / genetics. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Leukemia, Myeloid.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15899384.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human; 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.

Arsenic trioxide is now considered the standard agent in treatment of refractory cases of acute promyelocytic leukemia (APL).

Arsenic trioxide was given in a dosage of 0.15 mg kg(-1) and remission rate, survival rate, toxicities and effect on vascular density of bone marrow was studied.

Treatment efficacy results showed 100% complete remission rate after median of 30 days and 72% survival rate after median 860 days of follow-up.

The results imply that arsenic trioxide is an effective anti-leukemia and anti-angiogenesis agent in new cases of APL.

[MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

[MeSH-minor] Adolescent. Adult. Bone Marrow / blood supply. Bone Marrow / drug effects. Bone Marrow / pathology. Disease Progression. Female. Follow-Up Studies. Humans. Immunohistochemistry. Leukocytosis / chemically induced. Leukocytosis / pathology. Male. Middle Aged. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Recurrence. Remission Induction. Survival Rate. Time Factors. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Leuk Lymphoma. 2006 Apr;47(4):777. Tavangar, Mohammad [corrected to Tavangar, S Mohammad]

(PMID = 16321832.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.

We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL).

Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23 abnormalities, but therapy-related APL (t-APL) is less common, and documentation of nine cases of t-APL after mitoxantrone therapy for MS suggests a specific association.

[MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Promyelocytic, Acute / chemically induced. Mitoxantrone / adverse effects. Multiple Sclerosis / drug therapy

[MeSH-minor] Chromosomes, Human, Pair 11 / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Remission Induction. Translocation, Genetic

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Multiple Sclerosis.

MedlinePlus Health Information. consumer health - Multiple Sclerosis.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Cancer Genet Cytogenet. 2008 Oct 15;186(2):130

(PMID = 18406875.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; BZ114NVM5P / Mitoxantrone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of acute promyelocytic leukemia.

Cure of acute promyelocytic leukemia (APL) is now a possibility for most patients through the use of state-of-the-art treatments, which include simultaneous administration of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy for induction and consolidation, as well as ATRA-based maintenance.

However, HSCT plays an important role for patients in second complete remission.

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

SciCrunch. DrugBank: Data: Chemical .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17124054.001).

[ISSN] 1520-4391

[Journal-full-title] Hematology. American Society of Hematology. Education Program

[ISO-abbreviation] Hematology Am Soc Hematol Educ Program

[Language] ENG

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 42

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.

The T cell-lineage marker CD2 is sometimes expressed in acute promyelocytic leukemia (APL), and CD2 expression is reported to correlate with some clinical characteristics.

[MeSH-major] Antigens, CD2 / analysis. Leukemia, Promyelocytic, Acute / pathology

[MeSH-minor] Adult. Antigens, Neoplasm / analysis. Cell Shape. Humans. Immunophenotyping. Leukocyte Count. Leukocytosis / etiology. Middle Aged. Prognosis. Remission Induction. Risk Factors. Survival Analysis. T-Lymphocytes

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16178910.001).

[ISSN] 0141-9854

[Journal-full-title] Clinical and laboratory haematology

[ISO-abbreviation] Clin Lab Haematol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD2; 0 / Antigens, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia.

The use of all-trans retinoic acid (ATRA) has markedly improved the survival of patients with acute promyelocytic leukemia (APL), making it potentially curable.

However, the identification of prognostic markers predictive of durable remission remains an important aspect in risk-adjusted treatment algorithms.

[MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / genetics. DNA Methylation. Leukemia, Promyelocytic, Acute / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16753865.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p15

[Number-of-references] 71

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Long-term survival analysis in 170 cases of acute promyelocytic leukemia].

This study was aimed to investigate various factors influencing long-term survival in patients with acute promyelocytic leukemia.

Newly diagnosed patients with APL entering complete remission (CR) were followed up for 6 to 185 months (n = 170) from January 1990 to December 2004.

Univariate and multivariate analysis of 8 potential factors influencing survival and prognosis were carried out with Log-Rank and Cox regression method, including sex, age, initial WBC count, the level of lactic hydrogenase (LDH), first induction regimen, time from induction therapy to CR, post-remission therapy, negative or positive rate of PML-RAR alpha and follow-up of reverse transcription-polymerase chain reaction (RT-PCR).

Univariate analysis revealed that initial WBC count, first induction regimen, time from induction therapy to CR, type of post-remission therapy and persistent negative RT-PCR in remission were important prognostic factors for long-term survival.

Multivariate study demonstrated that only type of post-remission therapy was associated with RFS and OS.

It is concluded that the post-remission treatment combining ATRA, As(2)O(3) and chemotherapy would significantly improve the long-term survival of APL patients entering CR(1).

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16800915.001).

[ISSN] 1009-2137

[Journal-full-title] Zhongguo shi yan xue ye xue za zhi

[ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi

[Language] CHI

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.

The objective of our study was to evaluate high-dose cytarabine in consolidation therapy in patients with newly diagnosed acute promyelocytic leukemia (APL).

In total, 72 patients (88%) achieved a complete remission, and 10 patients (12%) died from early/hypoplastic death (ED/HD).

White blood cell count above 10.0 x 10(9)/l at diagnosis and additional chromosomal aberrations were unfavorable prognostic markers for OS, whereas no prognostic markers for RFS were identified including FLT3 mutations.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Mitoxantrone / administration & dosage. Tretinoin / administration & dosage

[MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Remission Induction. fms-Like Tyrosine Kinase 3

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. NOVANTRONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Leukemia. 2005 Jun;19(6):913-5 [15843820.001]

(PMID = 15843821.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Proto-Oncogene Proteins; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; BZ114NVM5P / Mitoxantrone; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; ZRP63D75JW / Idarubicin; AIDA protocol; MAC chemotherapy protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Retinoic acid in treating acute promyelocytic leukemia with hyperleukocytosis and its therapeutic strategy].

In order to investigate the occurrence of hyperleukocytosis in treating acute promyelocytic leukemia (APL) patients with all trans retinoic acid (ATRA) and to explore the influence of the level of leucocyte on curative effect of ATRA, the APL patients were divided into three different groups according to the count of leucocyte in peripheral blood.

Total remission rates in the second group and in the third group were 91.3%.

The remission rates in the first, second and third groups were 100%, 87.5% and 90.9%, respectively.

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18426682.001).

[ISSN] 1009-2137

[Journal-full-title] Zhongguo shi yan xue ye xue za zhi

[ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi

[Language] CHI

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR.

BACKGROUND: Real-time quantitative RT-PCR (RQ-PCR) assay has become a vital tool to monitor residual disease of leukemia.

We aimed to assess the methodology of RQ-PCR and its clinical applications in monitoring molecular kinetics of 36 newly diagnosed cases of acute promyelocytic leukemia patients with t (15;.

No false positive results occurred in 40 non-acute promyelocytic leukemia samples.

Although the time to attain hematological complete remission was similar in both groups, the time to achieve molecular remission of group 1 was significantly shorter than that of group 2 (61 days vs 75 days, P = 0.034).

The rate of molecular remission within 70 days was higher in group 1 than in group 2 (75.00% vs 38.46%, P = 0.036).

Arsenics, all-trans retinoic acid and mitoxantrone triad induction treatment of acute promyelocytic leukemia is superior to two-drug combination induction therapy in terms of the molecular response.

[MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18028775.001).

[ISSN] 0366-6999

[Journal-full-title] Chinese medical journal

[ISO-abbreviation] Chin. Med. J.

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells].

OBJECTIVE: To investigate the mechanism of tetra-arsenic tetra-sulfide (As4S4) in inducing apoptosis of acute promyelocytic leukemia (APL) cells.

The mRNA expression levels of these apoptosis related genes in the peripheral blood of APL patients treated with As4S4 pre- and post-remission were examined by RT-PCR.

RT-PCR results showed that the expression ratios of Apaf-1, caspase-9 and PNAS-2 in APL patients pre- and post-remission were 2.31 and 3.21, 0.99 respectively.

[MeSH-minor] Arsenic / pharmacology. Cell Line, Tumor. Gene Expression / drug effects. Gene Expression Profiling. Humans. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology. Oligonucleotide Array Sequence Analysis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16778962.001).

[ISSN] 1671-167X

[Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[ISO-abbreviation] Beijing Da Xue Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Apoptotic Protease-Activating Factor 1; 0 / Arsenicals; 0 / PNAS-2 protein, human; 0 / RNA, Messenger; 0 / Sulfides; N712M78A8G / Arsenic

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.

We assessed concentrations of arsenic trioxide (As(2)O(3)) and its metabolites in the plasma and cerebrospinal fluid in acute promyelocytic leukemia patients who achieved complete remission with intravenous As(2)O(3).

[MeSH-major] Antineoplastic Agents / cerebrospinal fluid. Arsenicals / cerebrospinal fluid. Leukemia, Promyelocytic, Acute / cerebrospinal fluid. Oxides / cerebrospinal fluid

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.

(PMID = 19733394.001).

[ISSN] 1873-5835

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.

Acute promyelocytic leukemia (APL) is characterized by a specific t(15;17) chromosomal translocation that yields the PML/RARA fusion gene.

Both agents directly target PML/RARA-mediated transcriptional repression and protein stability, inducing to various extent promyelocyte differentiation and clinical remission of APL patients.

The RA-As association, which synergizes for PML/RARA degradation but not for differentiation, rapidly clears leukemia initiating cells (LIC), resulting in APL eradication in murine APL models, but also in several APL clinical trials.

[MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Oncogene Proteins, Fusion / metabolism

[MeSH-minor] Animals. Drug Delivery Systems. Drug Synergism. Humans. Leukemia, Experimental / metabolism. Mice

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19808868.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

[Number-of-references] 65

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of acute promyelocytic leukemia during pregnancy.

Management of the pregnant patient with acute promyelocytic leukemia (APL) is a challenge.

Complete remission was reported in 35 (83%) of 42 patients.

[MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Pregnancy.

MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19476422.001).

[ISSN] 1875-9114

[Journal-full-title] Pharmacotherapy

[ISO-abbreviation] Pharmacotherapy

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

[Number-of-references] 71

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinical and laboratory features of patients with CD34(+) acute promyelocytic leukemia].

OBJECTIVE: To explore the expression of CD34 in patients with acute promyelocytic leukemia (APL) and investigate the clinical and laboratory features of CD34(+) APL patients.

The clinical features including age, gender, abnormal values of the peripheral hemogram before treatment, the complete remission (CR) rate and the incidence of DIC and laboratory data such as the results of morphology, immunology, cytogenetics and molecular biology (MICM) between those two groups were compared.

There were no statistically significant differences between the two groups compared in respect of complete remission (CR) rate and the incidence of DIC (P > 0.05).

CONCLUSION: CD34(+) acute promyelocytic leukemia is a unique subtype of APL with different biological characteristics.

[MeSH-major] Antigens, CD34 / blood. Leukemia, Promyelocytic, Acute / immunology. Phenotype

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD2 / blood. Antigens, CD7 / blood. Antineoplastic Agents / therapeutic use. Child. Disseminated Intravascular Coagulation / etiology. Female. Humans. Immunophenotyping. Male. Middle Aged. Nuclear Proteins / metabolism. Proto-Oncogene Proteins c-kit / blood. Receptors, Retinoic Acid / metabolism. Remission Induction. Retrospective Studies. Transcription Factors / metabolism. Translocation, Genetic. Tretinoin / therapeutic use. Tumor Suppressor Proteins / metabolism. Young Adult

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19615259.001).

[ISSN] 0253-3766

[Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]

[ISO-abbreviation] Zhonghua Zhong Liu Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antigens, CD2; 0 / Antigens, CD34; 0 / Antigens, CD7; 0 / Antineoplastic Agents; 0 / Nuclear Proteins; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human; 5688UTC01R / Tretinoin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.

Acute promyelocytic leukemia (APL) is a form of acute myeloid leukemia characterized by peculiar biologic features and a unique sensitivity to differentiation therapy with all-trans retinoic acid (ATRA).

However, it is conceivable that the use of this agent in APL will increase in the near future in light of its capability to induce molecular remission even in advanced disease.

[MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16562371.001).

[ISSN] 1543-0790

[Journal-full-title] Clinical advances in hematology & oncology : H&O

[ISO-abbreviation] Clin Adv Hematol Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; S7V92P67HO / arsenic trioxide

[Number-of-references] 53

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Acute promyelocytic leukemia (APL) is characterized by a t(15;17) translocation that yields a PML/RARA fusion protein.

Both retinoic acid (RA) and arsenic trioxide directly target PML/RARA-mediated transcriptional repression and protein stability, inducing rapid differentiation of the promyelocytes and clinical remission in most APL patients.

RA also triggers growth arrest and progressive clearance of leukemia initiating cells (LIC), both ex vivo and in vivo.

Suboptimal RA concentrations or expression of the PLZF/RARA variant allows complete RA-induced differentiation, but neither LIC clearance nor disease remission.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Granulocyte Precursor Cells / drug effects. Leukemia, Promyelocytic, Acute / drug therapy. Oncogene Proteins, Fusion / genetics. Oxides / therapeutic use. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Haematologica. 2006 Dec;91(12 Suppl):ECR58 [17194664.001]

[Cites] J Exp Med. 2004 Apr 19;199(8):1163-74 [15096541.001]

[Cites] N Engl J Med. 1993 Jul 15;329(3):177-89 [8515790.001]

[Cites] Trends Cell Biol. 2005 Sep;15(9):494-501 [16084092.001]

[Cites] Mol Cell. 2000 May;5(5):811-20 [10882117.001]

[Cites] Nat Rev Cancer. 2005 Oct;5(10 ):821-7 [16175176.001]

[Cites] Blood. 1995 Feb 15;85(4):1083-94 [7849296.001]

[Cites] Ann Oncol. 2006 Jan;17(1):131-4 [16227315.001]

[Cites] Cancer Res. 2005 Oct 1;65(19):8754-65 [16204045.001]

[Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]

[Cites] EMBO J. 2009 Jan 7;28(1):34-47 [19078967.001]

[Cites] Cancer Cell. 2006 Feb;9(2):73-4 [16473273.001]

[Cites] Blood. 1995 May 15;85(10):2643-53 [7742522.001]

[Cites] Blood. 2009 Dec 24;114(27):5499-511 [19855079.001]

[Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]

[Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]

[Cites] Nat Med. 2008 Dec;14(12):1333-42 [19029980.001]

[Cites] Cell. 1997 Jul 11;90(1):97-107 [9230306.001]

[Cites] J Exp Med. 2002 Nov 18;196(10):1373-80 [12438428.001]

[Cites] Cancer Cell. 2007 Jul;12 (1):23-35 [17613434.001]

[Cites] Blood. 1998 Oct 1 ;92 (7):2244-51 [9746761.001]

[Cites] Blood. 2002 Feb 1;99(3):1014-22 [11807007.001]

[Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]

[Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10173-8 [10954752.001]

[Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]

[Cites] Cancer Cell. 2009 Jan 6;15(1):7-8 [19111876.001]

[Cites] Cancer Cell. 2007 Jul;12 (1):36-51 [17613435.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16608-13 [16275922.001]

[Cites] Nature. 2008 Jun 19;453(7198):1072-8 [18469801.001]

[Cites] Nat Cell Biol. 2008 May;10 (5):538-46 [18408734.001]

[Cites] J Exp Med. 2001 Jun 18;193(12 ):1361-71 [11413191.001]

[Cites] Nat Rev Mol Cell Biol. 2007 Dec;8(12 ):1006-16 [17928811.001]

[Cites] J Exp Med. 1999 Apr 5;189(7):1043-52 [10190895.001]

[Cites] N Engl J Med. 2009 Feb 26;360(9):928-30 [19246367.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]

[Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):M53-61 [9426202.001]

[Cites] Blood. 2001 Jan 1;97(1):73-80 [11133744.001]

[Cites] Oncogene. 1996 Jun 6;12 (11):2451-9 [8649787.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]

[Cites] Nature. 1998 Feb 19;391(6669):811-4 [9486654.001]

[Cites] Cancer Cell. 2005 Feb;7(2):143-53 [15710327.001]

[Cites] Blood. 1999 May 15;93(10 ):3167-215 [10233871.001]

[Cites] Genes Dev. 2009 May 15;23 (10 ):1195-206 [19451220.001]

[Cites] Cancer Cell. 2007 Jun;11(6):513-25 [17560333.001]

[Cites] Nat Genet. 1998 Feb;18(2):126-35 [9462740.001]

[Cites] Leukemia. 1998 Nov;12(11):1829-33 [9823961.001]

[Cites] EMBO J. 1994 Mar 1;13(5):1073-83 [8131741.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14807-12 [10611294.001]

[Cites] Oncogene. 2002 May 13;21(21):3445-58 [12032781.001]

[Cites] Clin Cancer Res. 2009 Oct 15;15(20):6321-6 [19808868.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9548-53 [16769902.001]

[Cites] Nat Cell Biol. 2008 May;10 (5):547-55 [18408733.001]

[Cites] Cell. 1994 Jan 28;76(2):333-43 [8293467.001]

[Cites] Leukemia. 2009 Aug;23(8):1462-71 [19322209.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]

[Cites] Leuk Lymphoma. 2006 Jun;47(6):1062-8 [16840198.001]

[Cites] Blood. 2009 Dec 24;114(27):5415-25 [19797526.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7 [19225113.001]

[Cites] Oncogene. 2001 Oct 29;20(49):7140-5 [11704842.001]

[Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]

[Cites] Blood. 1999 Jul 15;94(2):793-802 [10397747.001]

[Cites] Mol Cell. 2000 May;5(5):821-30 [10882118.001]

[Cites] Cancer Cell. 2010 Feb 17;17(2):173-85 [20159609.001]

[Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]

[Cites] Nature. 1998 Feb 19;391(6669):815-8 [9486655.001]

(PMID = 20455087.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The design of selective and non-selective combination therapy for acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) is an unique subtype of acute myeloid leukemia typically carrying a specific reciprocal chromosome translocation, t(15;17), leading to the expression of a leukemia-generating fusion protein, PML-RARalpha.

Nearly all de novo APL patients undergo clinical remission when treated with ATRA plus chemotherapy or with the combinational selective therapy, ATRA plus As2O3.

[MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17217047.001).

[ISSN] 0070-217X

[Journal-full-title] Current topics in microbiology and immunology

[ISO-abbreviation] Curr. Top. Microbiol. Immunol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA93533

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 114

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [FLT3 internal tandem duplication in patients with acute promyelocytic leukemia].

OBJECTIVE: To analyze the mutation of FLT3 internal tandem duplication (FLT3-ITD) in bone marrow cells from patients with newly-diagnosed acute promyelocytic leukemia (APL).

Out of FLT3-ITD positive patients, 18/20 (90%) obtained complete remission and 16 evaluable patients (2 lost follow-up) remained in first remission in a median follow-up of 26 (11-47) months.

[MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Mutation. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17939400.001).

[ISSN] 0253-2727

[Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.

Alterations of the FLT3 gene, in the form of internal tandem duplications (ITD) and D835 point mutations, occur frequently in acute promyelocytic leukemia (APL).

Both ITD and D835 mutations were associated with shortened event-free survival (P = 0.048 and P = 0.029, respectively), but there was no correlation between disease-free survival among the 61 patients who achieved complete remission and the presence of FLT3 mutations (P = 0.543 for ITD and P = 0.277 for D835).

In Korean patients, however, FLT3 mutations were associated with higher leukemic burdens and early deaths before remission resulting in inferior prognosis.

[MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Mutation / genetics. fms-Like Tyrosine Kinase 3 / genetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17064989.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment concepts of acute promyelocytic leukemia.

In the past, acute promyelocytic leukemia (APL) was associated with a high risk of early mortality resulting from severe coagulopathy, frequently inducing fatal cerebral hemorrhage.

With the introduction of the differentiating agent all-trans retinioc acid (ATRA) APL has changed to the best curable subtype of acute myeloid leukemia (AML).

With ATRA and chemotherapy approximately 70-80% of patients with newly diagnosed APL achieve long-term remission and are probably cured.

PML/RARalpha, the molecular fusion transcript of the specific translocation t(15;17) represents not only the target for ATRA but also permits a precise diagnosis and provides a marker for the identification of minimal residual or recurrent disease (MRD).

Approximately 50% of the patients in first relapse can achieve long-lasting second remission and might be cured with salvage regimens.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / therapy. Stem Cell Transplantation

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16236522.001).

[ISSN] 1040-8428

[Journal-full-title] Critical reviews in oncology/hematology

[ISO-abbreviation] Crit. Rev. Oncol. Hematol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Ireland

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 121

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications.

Despite recent advances in the treatment of acute promyelocytic leukemia (APL), early mortality and relapses still occur.

Forty-two patients (77%) achieved first remission (CR1).

[MeSH-major] Gene Duplication. Leukemia, Promyelocytic, Acute / genetics. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics

[MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / administration & dosage. Female. Follow-Up Studies. Humans. India / epidemiology. Leukocyte Count. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Prognosis. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. DAUNORUBICIN .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. MERCAPTOPURINE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17454189.001).

[ISSN] 1607-8454

[Journal-full-title] Hematology (Amsterdam, Netherlands)

[ISO-abbreviation] Hematology

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; E7WED276I5 / 6-Mercaptopurine; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].

OBJECTIVE: To evaluate the prevalence of Fms-Like tyrosine kinase 3 (FLT3) mutations including internal tandem duplication (ITD) of juxtamembrane region and point mutation in the second tyrosine kinase domain (TKD) in acute promyelocytic leukemia (APL) and its clinical significance.

For FLT3-ITD positive patients, the incidences of retinoic acid syndrome (RAS) and disseminated intravascular coagulation (DIC) were 41.7% and 65.4%, respectively, being higher than that of FLT3-wt patients, while their complete remission (CR) rate was lower (69.2% vs 90.3%, P < 0.05).

[MeSH-major] Leukemia, Promyelocytic, Acute / genetics. Point Mutation. Tandem Repeat Sequences. fms-Like Tyrosine Kinase 3 / genetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19176014.001).

[ISSN] 0253-2727

[Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of acute promyelocytic leukemia by retinoids.

We review the role of all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).

Combination treatment probably also reduces the incidence of initial failures, and complete remission (CR) rates greater than 90% are now regularly reported in large multicenter trials.

[MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17217041.001).

[ISSN] 0070-217X

[Journal-full-title] Current topics in microbiology and immunology

[ISO-abbreviation] Curr. Top. Microbiol. Immunol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

[Number-of-references] 132

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Long-term therapeutic outcome of patients with acute promyelocytic leukemia].

OBJECTIVE: To analyze the long-term therapeutic outcome of patients with acute promyelocytic leukemia(APL).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17649719.001).

[ISSN] 0253-2727

[Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 5688UTC01R / Tretinoin

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia].

OBJECTIVE: To report the results of curative and adverse effects of compound huangdai tablet (CHDT) as induction therapy for 193 patients with acute promyelocytic leukemia (APL).

RESULTS: One hundred and ninety-three patients achieved complete remission (CR), 78.8% of whom in 30 to 60 days with an average time of 44.3 d.

[MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy. Phytotherapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Herbal Medicine.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19954593.001).

[ISSN] 0253-2727

[Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi

[Language] chi

[Publication-type] Clinical Trial; English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Plant Preparations

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of relapsed or refractory acute promyelocytic leukemia.

Current treatment for acute promyelocytic leukemia (APL) usually includes an induction phase with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy, followed by a consolidation phase of anthracycline-based chemotherapy and maintenance therapy with ATRA with or without low-dose chemotherapy for 1-2 years.

This treatment strategy results in a high complete remission (CR) rate of about 90% and an overall survival rate of 80%.

Hematopoietic stem cell transplantation is becoming a common strategy after achieving remission with ATO.

Autologous transplant appears to have a more favorable outcome than allogeneic transplant in this setting, particularly when carried out during second remission, primarily because of significantly higher treatment-related mortality with allogeneic transplants.

[MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17336255.001).

[ISSN] 1521-6926

[Journal-full-title] Best practice & research. Clinical haematology

[ISO-abbreviation] Best Pract Res Clin Haematol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 0 / gemtuzumab; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; S7V92P67HO / arsenic trioxide

[Number-of-references] 52

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.

Retinoic acid and arsenic trioxide target the protein stability and transcriptional repression activity of the fusion oncoprotein PML-RARA, resulting in regression of acute promyelocytic leukemia (APL).

Here we show that retinoic acid also triggers growth arrest of leukemia-initiating cells (LICs) ex vivo and their clearance in PML-RARA mouse APL in vivo.

Retinoic acid treatment of mouse APLs expressing the fusion protein PLZF-RARA triggers full differentiation, but not LIC loss or disease remission, establishing that differentiation and LIC loss can be uncoupled.

Thus, whereas transcriptional activation of PML-RARA is likely to control differentiation, its catabolism triggers LIC eradication and long-term remission of mouse APL.

[MeSH-major] Leukemia, Promyelocytic, Acute / metabolism. Oncogene Proteins, Fusion / metabolism

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. L-SERINE .

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Cancer Cell. 2009 Jan 6;15(1):7-8 [19111876.001]

[ErratumIn] Nat Med. 2009 Jan;15(1):117

(PMID = 19029980.001).

[ISSN] 1546-170X

[Journal-full-title] Nature medicine

[ISO-abbreviation] Nat. Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PLZF-RARalpha fusion protein, mouse; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 452VLY9402 / Serine; 5688UTC01R / Tretinoin; E0399OZS9N / Cyclic AMP; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.

In the present study, 90 patients with newly diagnosed acute promyelocytic leukemia (APL) were studied for all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)) combination treatment in remission induction and postremission therapy.

In addition, 20 APL patients who had achieved complete remission (CR) with an ATRA-based regimen received ATRA/As(2)O(3) combination for consolidation and maintenance were also enrolled.

The drug toxicity profile showed that with the use of As(2)O(3), the incidence of hepatotoxicity was obviously high during remission induction but decreased significantly during postremission treatment.

We conclude that APL patients may benefit from the early use of the combination of ATRA and As(2)O(3), in either remission induction or consolidation/maintenance.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adolescent. Adult. Aged. Arsenicals / administration & dosage. Arsenicals / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Oxides / administration & dosage. Oxides / adverse effects. Remission Induction / methods. Survival Rate. Time Factors. Tretinoin / administration & dosage. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2009 S. Karger AG, Basel.

[ErratumIn] Acta Haematol. 2009;121(4):243

(PMID = 19246888.001).

[ISSN] 1421-9662

[Journal-full-title] Acta haematologica

[ISO-abbreviation] Acta Haematol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Retrospective analysis of 76 children with acute promyelocytic leukemia].

OBJECTIVE: There are very limited data on childhood acute promyelocytic leukemia (APL), especially childhood APL treated with arsenic trioxide (As(2)O(3)).

RESULTS: Six cases failed to achieve hematological complete remission (CR) due to early death.

[MeSH-major] Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20021798.001).

[ISSN] 0578-1310

[Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics

[ISO-abbreviation] Zhonghua Er Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia.

A 67-year-old Japanese woman who presented with erythema on the abdomen and pancytopenia was found to have acute promyelocytic leukemia (APL).

She achieved complete remission and the gangrenous cheilitis slowly healed over the following 8 weeks.

[MeSH-major] Antineoplastic Agents / adverse effects. Cheilitis / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lancet. 2006 Jul 8;368(9530):147-56 [16829299.001]

[Cites] Blood. 1995 May 15;85(10):2643-53 [7742522.001]

[Cites] Can Vet J. 1995 Feb;36(2):106-7 [7728725.001]

[Cites] Rinsho Ketsueki. 1998 Jan;39(1):48-52 [9492553.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Br J Haematol. 1997 May;97(2):300-5 [9163592.001]

[Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]

[Cites] Pediatr Dermatol. 2003 Nov-Dec;20(6):519-23 [14651574.001]

[Cites] Ann Hematol. 2002 Feb;81(2):111-4 [11907794.001]

[Cites] Intern Med. 2005 May;44(5):480-3 [15942099.001]

[Cites] Clin Sci (Lond). 2007 Jun;112(7):375-84 [17324119.001]

(PMID = 20035486.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia.

It can be initial manifestation of myeloproliferative disorders or relapse of previously treated acute myeloblastic leukemia (AML).

We present two patients, one with AML-M2 and the other with acute promyelocytic leukemia (APL)-M3.

After remission induced by conventional chemotherapy, which continued for 3 and 10 years respectively, a myeloid sarcoma was diagnosed.

Two years after the diagnosis of myeloid sarcoma the patient died of haemorrhagic stroke.

[MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Sarcoma, Myeloid / pathology

Genetic Alliance. consumer health - Leukemia, Myeloid.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19145688.001).

[ISSN] 1107-0625

[Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology

[ISO-abbreviation] J BUON

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Greece

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Current therapeutic strategies in the management of acute myeloid leukemia].

Acute myeloid leukemia (AML) is a rare disease of the hematopoietic stem cell leading to uncontrolled proliferation of immature progenitor cells.

Diagnosis can reliably be confirmed by bone marrow aspiration, which also allows risk stratification by cytogenetic and molecular analysis.

Therapy of AML that should preferentially be performed in clinical studies comprises induction therapy for achievement of complete cytomorphological remission (CR) and postremission strategies consisting of consolidation and maintenance therapy for eradication of residual blasts.

To date, induction therapy will be performed independently of the individual risk constellation (with the exception of acute promyelocytic leukemia); however, postremission therapy is highly dependent on individual risk stratification.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Biopsy, Needle. Bone Marrow / pathology. Bone Marrow Purging. Bone Marrow Transplantation. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Remission Induction. Retreatment

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17426934.001).

[ISSN] 0723-5003

[Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)

[ISO-abbreviation] Med. Klin. (Munich)

[Language] ger

[Publication-type] English Abstract; Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine

[Number-of-references] 65

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease.

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that comprises about 10% of cases.

It is characterized by the accumulation of granulocytic cells blocked at the promyelocytic stage of differentiation in the bone marrow and the peripheral blood, life-threatening coagulopathy, and a remarkable response to treatment with all-trans-retinoic acid (ATRA), arsenic trioxide, and anthracyclines.

Current treatment strategies with ATRA and anthracycline-based chemotherapy has dramatically transformed APL into the most curable of all acute leukemias.

[MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Humans. Practice Guidelines as Topic. Remission Induction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16167012.001).

[ISSN] 1543-0790

[Journal-full-title] Clinical advances in hematology & oncology : H&O

[ISO-abbreviation] Clin Adv Hematol Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 69